** charts before earnings **
** charts after earnings **
Inovio Pharma misses by $0.02, beats on revs; updates pipeline :
- Reports Q4 (Dec) loss of $0.35 per share, $0.02 worse than the Capital IQ Consensus of ($0.33); revenues rose 44.1% year/year to $8.5 mln vs the $5.21 mln Capital IQ Consensus.
- Dr. J. Joseph Kim, President and CEO, said: "In 2016 Inovio made significant progress on all three focuses of its Vision 2020 plan, which are HPV-related precancer, immuno-oncology, and infectious diseases, with notable data, multiple trial completions, progressive clinical study preparations, and multiple valuable collaborations and funding agreements. In 2017 we expect to report immune response data from clinical studies in six different diseases; the initiation of our phase 3 study of cervical dysplasia and two immuno-oncology combination studies, one by MedImmune and one by Inovio; and additional business development steps. We look forward to a highly productive year in advancing our unique immunotherapy platform and products."
- Corporate Updates
- Inovio is planning to launch a phase 2 clinical study in 2017 for another HPV-related disease, vulvar intraepithelial neoplasia.
- Completed enrollment of 94 subjects in the phase 1 study of our PENNVAX-GP HIV immunotherapy. After completing extensive immunogenicity analyses, they expect to report data in 2H 2017.
No comments:
Post a Comment